Company intelligence / Profile preview

Pergamum AB

Solna, Stockholm region, Swedenlinkedin.com ↗

Ownership: Private
Employees: ~25
Development stage: Phase 2

Overview

The company had multiple programs in clinical development, including a Phase II trial with DPK-060 in outer ear infections, and successful Phase I/IIa clinical trial results for atopic dermatitis

Therapeutic areas: OtherDermatologyInfectious Diseases
Modalities: Therapeutic peptides
Industry: Biotech

Drug pipeline

3 assets

DPK-060

Phase 2

Indications: Atopic dermatitis, Outer ear infections

2 more assets in the full pipeline.

Request access →

Partnerships

Cadila Pharmaceuticals Ltd

Beyond the preview

Go deeper on Pergamum AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pergamum AB.

Explore the full profile